Please ensure Javascript is enabled for purposes of website accessibility

Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again

By Max Macaluso – Jan 14, 2014 at 8:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Why did Intercept shares tumble today?

High-flying biotech Intercept Pharmaceuticals (ICPT -2.25%) enjoyed a 516% gain last week, but shares have tumbled this week. After yesterday's 18% dive, shares dropped another 30% today. In the following video, analyst Max Macaluso discusses what caused today's drop and the key issues that long-term investors need to focus on.

Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and also owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.